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OBJECTIVE — Although management of type 1 diabetes improved dramatically in the
1980s, the effect on mortality is not clear.
RESEARCH DESIGN AND METHODS — We report trends in 30-year mortality using
the Allegheny County (Pennsylvania) childhood-onset (age 18 years) type 1 diabetes registry
(n  1,075) with diagnosis from 1965–1979, by dividing the cohort into three diagnosis year
cohorts (1965–1969, 1970–1974, and 1975–1979). Local (Allegheny County) mortality data
were used to calculate standardized mortality ratios (SMRs).
RESULTS — As of 1 January 2008, vital status was ascertained for 97.0% of participants (n 
1,043) when mean age  SD and duration of diabetes were 42.8  8.0 and 32.0  7.6 years,
respectively. The 279 deaths (26.0%) observed were 7 times higher than expected (SMR 6.9
[95% CI 6.1–7.7]). An improving trend in SMR was seen by diagnosis cohort at 30 years of
diabetes duration (9.3 [7.2–11.3], 7.5 [5.8–9.2], and 5.6 [4.0–7.2] for 1965–1969, 1970–
1974, and 1975–1979, respectively). Although no sex difference in survival was observed (P 
0.27), female diabetic patients were 13 times more likely to die than age-matched women in the
generalpopulation(SMR13.2[10.7–15.7]),muchhigherthantheSMRformen(5.0[4.0–6.0]).
Conversely, whereas 30-year survival was signiﬁcantly lower in African Americans than in
Caucasians (57.2 vs. 82.7%, respectively; P  0.001), no differences in SMR were seen by race.
CONCLUSIONS — Although survival has clearly improved, those with diabetes diagnosed
mostrecently(1975–1979)stillhadamortalityrate5.6timeshigherthanthatseeninthegeneral
population,revealingacontinuingneedforimprovementsintreatmentandcare,particularlyfor
women and African Americans with type 1 diabetes.
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T
ype 1 diabetes is known to be asso-
ciatedwithanincreasedriskofmor-
tality compared with that for the
general population. Type 1 diabetes
leads to hyperglycemia, which is linked
to a number of acute (e.g., diabetic ke-
toacidosis)andchronic(e.g.,diabeticne-
phropathy and cardiovascular disease)
complications (1). With the advent of
blood glucose self-monitoring, A1C test-
ing, and use of ACE inhibitors, treatment
for type 1 diabetes improved tremen-
dously during the 1980s and 1990s (2–4).
Despite these improvements, however,
type 1 diabetes complications still fre-
quently lead to premature mortality. Re-
cent reports from Western Europe have
shown long-term mortality (15 years
follow-up) in type 1 diabetes to be 3–4
timesthatofthegeneralpopulation(5,6);
however, long-term population-based
data on type 1 diabetes mortality in the
U.S. have been limited, and mortality
ranges from 5 to 7 times that of the gen-
eral population (7).
Usingalargepopulation-basedtype1
diabetes cohort in Allegheny County
(Pittsburgh), Pennsylvania diagnosed be-
tween1965and1979,wenowextendthe
long-term mortality trends to between
28 and 43 years of follow-up after diag-
nosis and explore differences in mortal-
ity rates by sex, race (Caucasian vs.
African American), and calendar year of
type 1 diabetes diagnosis.
RESEARCH DESIGN AND
METHODS— The Allegheny County
Type 1 Diabetes Registry cohort included
all individuals with a diagnosis of child-
hood-onset (aged 18 years) type 1 dia-
betes in Allegheny County between 1
January 1965 and 31 December 1979
who were given insulin treatment at diag-
nosis.Individualswereidentiﬁedthrough
a periodic review of hospital records and
validated by contacting pediatricians
throughout the county, with ascertain-
ment exceeding 95% (8). Individuals
were excluded if diabetes developed due
to a secondary cause (i.e., cystic ﬁbrosis,
Down syndrome, or use of steroids). A
total of 1,075 eligible participants were
included in the Allegheny County Type 1
Diabetes Registry cohort, which has been
part of an international study (Diabetes
Epidemiology Research International
[DERI]) comparing mortality in popula-
tion-based type 1 diabetes cohorts across
countries(9–11).Thestudyprotocolwas
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Vital status was determined as of 1
January 2008, by contacting all partici-
pants initially by letter with a health up-
date questionnaire and consent form.
Individualswhofailedtorespondtomail-
ings were contacted by telephone. Deaths
not initially identiﬁed through this pro-
cess were discovered by searching both
the Social Security Death Index (SSDI)
and the National Death Index (NDI).
Death certiﬁcates (or NDI data) were ob-
tained to conﬁrm each death. With one
exception, reports of all deaths were thus
conﬁrmed by either a death certiﬁcate or
the SSDI/NDI.
Statistical analysis
Distributional characteristics for each
variable were assessed for normality. Stu-
dent t test and one-way ANOVA were
used to compare variables between
groups, with adjustment for multiple
comparisons using the Bonferroni correc-
tion. Diagnosis year was categorized into
three groups (1965–1969, 1970–1974,
and 1975–1979) to evaluate temporal
trends in overall as well as sex- and race-
speciﬁc mortality. Age at diabetes onset
was categorized as prepubertal (10
years), peripubertal (10–14 years), and
postpubertal (14 years). The 
2 (or
Fisher exact) test was used to compare
categorical variables between groups, as
appropriate. Variables were then made
available in multivariable Cox propor-
tional hazards regression models using
backward selection. The proportional
hazards assumption was assessed visually
andconﬁrmedbytestingtime-dependent
interaction variables.
Expected mortality was estimated us-
ing the person-years method based on
general population life tables for Allegh-
eny County, Pennsylvania (12). Age-,
sex-, and race-adjusted standardized
mortalityratios(SMRs)werecalculatedas
the observed divided by the expected
number of deaths in each age, sex, and
race category, and 95% CIs were deter-
mined with the Poisson distribution.
Mortality rates and SMRs were compared
using rate ratio (RR) analyses and calcu-
lating 95% CIs (13). Statistical signiﬁ-
cance was considered at P  0.05. All
analyses were completed using SPSS 17.0
(SPSS, Chicago, IL).
RESULTS— Demographic character-
istics of the Allegheny County type 1 dia-
betes registry cohort are presented by sex
and race in Table 1. Vital status as of 1
January 2008 was veriﬁed for 1,043 par-
ticipants (ascertainment rate 97.0%) pro-
viding 34,363 total person-years of
follow-up.Vitalstatusveriﬁcationdidnot
differ by sex (P  0.11) or by age at dia-
betes onset (mean  SD, conﬁrmed
10.8  4.2 vs. unconﬁrmed 12.2  4.2
years; P  0.07). However, Caucasians
weremorelikelytobetracedthanAfrican
Americans (97.7 vs. 88.6%, respectively;
P  0.001). No differences in ascertain-
ment rates existed by diabetes diagnosis
year (data not shown).
Over a median 33.0 years of follow-
up, 279 total deaths (26.0%) occurred in
this population 138 male and 141 fe-
male), which was seven times higher than
that seen in the local general population
(SMR6.9[95%CI6.1–7.7]).Themean
SD age and duration of diabetes at fol-
low-up were 42.8  8.0 and 32.0  7.6
years, respectively. A much higher pro-
portion of African Americans died during
follow-up compared with Caucasians
(50.6vs.24.0%,respectively;P0.001).
As a result, the mean duration of fol-
low-up (diabetes duration) and the mean
age for African Americans in this cohort
wereboth5yearslessthanthatforCau-
casians (Table 1). Mean follow-up dura-
tion did not differ by sex, but mean age at
follow-up was signiﬁcantly lower for
women (P  0.02).
Overalland30-yearmortalityratesby
sex, race, and diabetes diagnosis cohort
arepresentedinTable2.Theoverallmor-
tality rate was 812 per 100,000 person-
years (95% CI 717–907). African
American mortality rates were signiﬁ-
cantly higher than Caucasian rates overall
and at the 30-year follow-up time point
(P0.001),andrateswerealsohigherin
women than in men, but this difference
was not signiﬁcant. Individuals with dia-
betes diagnosed at age 10 years (prepu-
bertal) in this type 1 diabetes cohort had
signiﬁcantly lower mortality rates than
thosewithperipubertal(age10–14years)
and postpubertal (age 14 years) onset
both overall and at the 30-year follow-up
(P  0.01). Mortality rates decreased in a
stepwise manner by diabetes diagnosis
cohort, with mortality in the 1965–1969
group signiﬁcantly higher than that in the
1975–1979 group overall (RR 1.86; P 
0.001)andat30yearsoffollow-up(1.51;
P  0.02). Given the differential ascer-
tainment by race, sensitivity analyses
wereperformedbasedonparticipantslost
to follow-up being either all dead or all
alive, and all signiﬁcant comparisons by
race, age at onset, and diagnosis cohort
remained robust to misclassiﬁcation.
Results from a multivariable Cox re-
gression model for overall mortality can
befoundinsupplementaryTable1(avail-
able in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc10-
1170/DC1). Sex was not signiﬁcant in the
multivariable model and was not in-
cluded in the ﬁnal model. Race, age at
onset, and year of diagnosis all signiﬁ-
cantlypredictedmortalityintype1diabetes
(both categorically and continuously). Ad-
justed mortality risk for African Ameri-
Table 1—Demographic characteristics of the Allegheny County Type 1 Diabetes Registry
cohort by sex and race as of 1 January 2008
Male Female Caucasian
African
American Total
n 558 517 996 79 1,075
Vital status conﬁrmed 97.8 (546) 96.1 (497) 97.7 (973) 88.6 (70)§ 97.0 (1,043)
Male — — 52.7 (525) 43.0 (34) 52.0 (559)
Caucasian 94.1 (525) 91.1 (471) — — 92.7 (996)
Diagnosis
1965–1969* 32.0 (179) 34.1 (176) 32.9 (328) 34.2 (27) 33.0 (355)
1970–1974* 38.1 (213) 34.4 (178) 36.7 (366) 31.6 (25) 36.4 (391)
1975–1979* 29.7 (166) 31.5 (163) 30.3 (302) 34.2 (27) 30.6 (329)
Age at diabetes diagnosis
(years) 11.0  4.3 10.8  4.0 10.8  4.2 11.4  4.3 10.9  4.2
Mean diabetes duration
(years)† 32.4  6.9 31.5  8.2 32.3  7.4 27.3  8.0§ 31.9  7.6
Mean age (years)† 43.4  7.6 42.3  8.4‡ 43.2  7.9 38.7  8.6§ 42.8  8.0
Person-years of follow-up 18,082.3 16,280.8 32,202.6 2,160.6 34,363.1
Data are % (n) or means  SD. *Ascertainment rates by diagnosis cohort: 1965–1969, 96.6%; 1970–1974,
97.4%;and1975–1979,97.0%.†Diabetesdurationandageatdeathorlastfollow-up.‡P0.05;§P0.01.
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Caucasians. Each additional year in age at
diabetes diagnosis conferred a 7% in-
creased mortality risk (hazard ratio 1.07,
95% CI 1.04–1.10), and risk of death de-
creased by 6% for each additional calen-
dar year of diabetes diagnosis over the
15-year period of diabetes diagnosis
(1965–1979) in this cohort.
Survival curves based on Kaplan-
Meier life table analyses are presented in
Fig.1.Cumulativesurvivalafterdiagnosis
of type 1 diabetes in this cohort was
98.2% at 10 years, 93.1% at 20 years,
80.9%at30years,and68.4%at40years.
Survival curves did not differ by sex (30-
year survival for men vs. women 82.6 vs.
79.0%) (Fig. 1A) but were signiﬁcantly
worse for African Americans than for
Caucasians (30-year survival 57.2 vs.
82.7%,respectively)(Fig.1B).Signiﬁcant
improvement in survival was seen across
the diabetes diagnosis cohorts (Fig. 1C),
and, when separated by sex or race (sup-
plementary Fig. 1A–D, available in an on-
line appendix), a declining trend in
mortality was seen across all race and sex
groups. However, only survival in men
(P  0.02) and in Caucasians (P  0.05)
showed a signiﬁcant improvement across
diagnosis cohorts. Improvement in sur-
vival was also seen by age at diabetes on-
set, with the prepubertal group (age 10
years) having signiﬁcantly better survival
than that in either the peri- or postpuber-
tal groups.
Finally, we calculated SMRs for this
cohort compared with the local age-, sex-
and race-matched general population
(supplementary Table 2, available in an
online appendix). Thirty years after diag-
nosisofdiabetes,mortalitywasmorethan
7 times higher than that seen in the local
general population (SMR 7.4 [95% CI
6.4–8.4]). The SMR for women is nearly
threetimeshigherthanthatformen(13.2
vs. 5.0; P  0.05), whereas the SMRs by
race were identical (African American 7.5
vs.Caucasian7.4).Animprovingtrendin
SMR was seen by diagnosis cohort at 30
years of diabetes duration (9.3 [7.2–
11.3], 7.5 [5.8–9.2], and 5.6 [4.0–7.2]
for 1965–1969, 1970–1974, and 1975–
1979, respectively).
The SMRs over time (5-year fol-
low-up intervals) are shown in Fig. 2 by
sex, race, and diabetes diagnosis cohort.
SMRs at 5-year follow-up are very high in
the Allegheny County cohort, especially
in women and in the earlier diagnosis co-
horts (1965–1969 and 1970–1974).
Mortality within the 1st year of diagnosis
(onset mortality) was relatively common
in this cohort (10 deaths) and occurred
almost exclusively in women (n  9),
driving the extremely high female SMR at
5 years of follow-up. Women have con-
sistentlyhadSMRsof10,whereasSMRs
inmenrangebetween1.8and5.0over30
yearsoffollow-up(Fig.2B).SMRsdidnot
differ signiﬁcantly by race but were con-
sistently lower in African Americans over
time (Fig. 2C). Steady improvements in
SMRs have been seen over time between
the 1965–1969 and 1975–1979 diagno-
sis cohorts, even after 30 years of type 1
diabetes duration (Fig. 2D).
CONCLUSIONS — These results ex-
pand on previously published reports
fromtheAlleghenyCountyType1Diabe-
tes Registry cohort with an additional 9
years of follow-up (7,9). Of note, now
with a range of 28–43 years of type 1
diabetes duration, the risk of dying is 7
times higher than that of the local general
population, with signiﬁcant improve-
ments in SMR for those with diabetes di-
agnosedmostrecentlyinthiscohort.This
SMR (7.4 [95% CI 6.4–8.4]) is higher
than that reported by Nishimura et al. (7)
for this cohort for the 1999 follow-up
(SMR 5.2 [4.4–6.0]), perhaps reﬂecting
an increasing effect of long-term compli-
cations,whicharekeepingmortalityrates
much higher in individuals with type 1
diabetes compared with the general
population.
This is the largest population-based
type 1 diabetes cohort with at least 25
years of follow-up in the U.S. A recent
population-based 20-year follow-up
studyinNewZealandshowedthehighest
SMRs in individuals with type 1 diabetes
diagnosed at age 30 (3.3 for men and
4.3 for women) (14). A nationwide Nor-
wegian cohort with childhood-onset (age
15 years) type 1 diabetes recently re-
ported SMRs of 3.9 (male) and 4.0 (fe-
male) after 20 years of follow-up (6).
Similar results were seen by sex in the
Table 2—Overall and 30-year mortality rates by sex, race, and diabetes diagnosis cohort
Overall 30-year
Deaths
Follow-up time
(person-years)
Mortality rate (95% CI) per
100,000 person-years Deaths
Follow-up time
(person-years)
Mortality rate (95% CI) per
100,000 person-years
Overall 26.0 (279) 34,363.1 811.9 (716.6–907.2) 18.8 (202) 30,046.2 672.3 (579.6–765.0)
Sex
Male 24.7 (138) 18,082.3 763.2 (635.8–890.5) 17.0 (95) 15,805.4 601.1 (480.2–721.9)
Female 27.3 (141) 16,280.8 866.1 (723.1–1,009.0) 20.7 (107) 14,240.8 751.4 (609.0–893.7)
Race†
Caucasian 24.0 (239) 32,202.6 742.2 (648.1–836.3) 17.1 (170) 28,016.9 606.8 (515.6–698.0)
African American 50.6 (40) 2,160.6 1,851.3 (1,277.6–2,425.1)* 40.5 (32) 2,029.3 1,576.9 (1,030.5–2,123.3)*
Age at onset†
10 years 20.7 (84) 13,530.3 620.8 (488.1–753.6) 11.9 (48) 11,623.9 412.9 (296.1–529.8)
10–14 years 28.6 (112) 12,368.0 905.6 (737.8–1,073.3)* 22.7 (89) 10,853.8 820.0 (649.6–990.4)*
14 years 29.9 (83) 8,464.9 980.5 (769.6–1,191.5)* 23.4 (65) 7,568.6 858.8 (650.0–1,067.6)*
Diagnosis cohort‡
1965–1969 37.2 (132) 12,277.6 1,075.1 (891.7–1,258.5) 22.3 (79) 9,877.2 799.8 (623.4–976.2)
1970–1974 23.5 (92) 12,584.8 731.0 (581.7–880.4)* 18.9 (74) 10,937.9 676.5 (522.4–830.7)
1975–1979 16.7 (55) 9,500.7 578.9 (425.9–731.9)* 14.9 (49) 9,231.1 530.8 (382.2–679.4)*
Data are % (n) unless otherwise indicated. *P  0.05 for rate ratio compared with ﬁrst group within each category. †P  0.01 for 
2 comparisons of deaths overall
and at 30-year follow-up. ‡P  0.01 for 
2 comparisons of deaths overall only.
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13.4 years of follow-up (male SMR 2.7;
female SMR 4.0) (15). Other recent re-
portsofall-causemortalityinpopulation-
based cohorts of type 1 diabetes exist,
with SMRs ranging from 1.8 to 4.2, but
their follow-up is limited (10 years),
which is the most likely reason for their
lower SMRs (16–18).
The markedly higher mortality seen
in our U.S. type 1 diabetes cohort is
clearly limited to women, for the men
have SMRs that are very comparable to
those reported in other long-term fol-
low-up studies (New Zealand, Norway,
and the U.K.) (6,14,15). However, di-
rectlycomparingSMRsacrosscountriesis
not appropriate because SMR differences
may result from either methodological or
cohort differences among these studies.
To what extent these differences reﬂect
our different health care system and a po-
tentiallackofaccessintheU.S.isdifﬁcult
todetermine.Nationalmeasuresofhealth
care performance and other national eco-
nomicmeasureshavebeenshowntocon-
tribute to complications in individuals
with type 1 diabetes (19).
Compared with their respective gen-
eral populations, women with type 1 dia-
betes had an SMR nearly 3 times higher
than that of men with type 1 diabetes.
This ﬁnding is partially reﬂective of the
much lower mortality rates for young
women in the general population. Long-
termmortalityratesdonotdifferbysexin
type 1 diabetes, consistent with our pre-
vious ﬁndings (7), but are markedly dif-
ferent from the ﬁndings in New Zealand,
Figure1—Life-tableanalysesbysex(A),race(B),diagnosiscohort(C),andageatonset(D)forindividualswithtype1diabetesbetween1965and
1979 in the Allegheny County type 1 diabetes registry cohort. P values calculated using the log-rank test. C: 1965–1969 vs. 1970–1974, P  0.02,
and 1965–1969 vs. 1975–1979, P  0.02. D: 10 vs. 10–14 years, P  0.002, and 10 vs. 14 years, P  0.001.
Mortality trends in type 1 diabetes
2576 DIABETES CARE, VOLUME 33, NUMBER 12, DECEMBER 2010 care.diabetesjournals.orgNorway, and the U.K. The respective
male-to-female mortality RRs for these
studies are 1.23 in New Zealand, 2.26 in
Norway, and 1.29 in the U.K compared
with 0.80 for our study. The reason for
this discrepancy is unclear, but it appears
that female sex completely lost its general
survival advantage in our diabetes
population.
Despite race being a signiﬁcant pre-
dictor of mortality within the Allegheny
County cohort (hazard ratio 3.2), no dif-
ferences in SMR were seen by race, the
African American SMR tending to be
lowerthantheCaucasianSMRduringfol-
low-up (Fig. 2C). This seemingly contra-
dictory result can be explained by the
extremely high mortality rates seen in
young African-Americans in the general
population, particularly resulting from
violent deaths (20). Thus, although
mortality rates in type 1 diabetes are
2–3 times higher in African Americans,
this excess can be attributed to the
backgroundAfricanAmericanmortality
rates and not to their diabetes. In a
3-year follow-up of 725 African Ameri-
cans with a mean 9-year duration of
type 1 diabetes, SMRs for men and
women were 7.0 and 10.5, respectively,
compared with those for the local general
African American population (21).
Temporal improvements in mortal-
ity have been reported in other type 1
diabetes studies. A report from the U.K.
on individuals in whom type 1 diabetes
was diagnosed (age 17 years) between
1940 and 1989 (n  845) showed a
fourfold decrease in SMRs between the
1940s cohort and the 1980s cohort (9.4
vs. 2.4, respectively) (22). A large Dan-
ish study of mortality reported an in-
crease of 15 years to the life expectancy
of type 1 diabetic patients diagnosed
overa40-yearperiodbetween1933and
1972(23).Thereasonsfortemporalim-
provements in our cohort remain un-
clear, but an examination of cause-
speciﬁc mortality is currently underway
to determine whether chronic diabetes
complications are being delayed or pre-
vented in the youngest cohort (1975–
1979) because of advances in care and
to help explain the dramatic differences
in SMRs by sex.
Onset mortality (death within the 1st
year of diagnosis) improved in this co-
hort. The 1975–1979 diagnosis cohort
had only one onset death compared with
four and ﬁve in the 1965–1969 and
Figure 2—SMRs and 95% CIs for the overall (A) Allegheny County Type 1 Diabetes Registry cohort and by sex (B), race (C), and diagnosis cohort
(D) at 5-year intervals of follow-up. C and D are spaced around the 5-year intervals for visual clarity; however, all SMRs are calculated at the same
5-year follow-up points.
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results are consistent with other studies
and correspond to improvement in diag-
nosis and care at onset (24).
Finally, this cohort is part of the
DERI Study group with Finland (n 
5,148) and Japan (n  1,410), explor-
ing mortality differences in childhood-
onset (age 18 years) type 1 diabetes in
three countries (all diagnosed between
1965and1979).Themostrecentreport
compared mortalities in Japan and Fin-
land after at least 15 years of follow-up
(5). The SMR for Japan was signiﬁcantly
higher (12.9) than that of Finland (3.7).
The comparable SMR for our popula-
tion was 5.8, which remains consistent
with previous reports from DERI show-
ing U.S. mortality rates sandwiched be-
tween Japanese and Finnish mortality
rates (9,11).
A few key limitations with this fol-
low-up study must be addressed. First,
these population-based data reﬂect the
type 1 diabetes experience of individuals
in Southwestern Pennsylvania with dia-
betes diagnosed between 1965 and 1979
and may not be representative of the en-
tire U.S., of individuals not of African
American or Caucasian ethnicity, or of
those with diabetes diagnosed earlier or
later than this cohort. In addition, 3% of
theAlleghenyCountytype1diabetesreg-
istry cohort was lost to follow-up, and vi-
tal status could not be determined for
these individuals. Thus, the mortality
rates might be slightly inﬂated. Thorough
searches of both the SSDI and the NDI
give us conﬁdence that most (if not all) of
these 32 individuals are still living. In ad-
dition,theanalysisislimitedtoonlyafew
key demographic variables (age at onset,
race, and sex), as other key socioeco-
nomic and clinical were not ascertained
for all participants at study inception (8).
Finally,becausediabetesinallindividuals
inthiscohortwasdiagnosedbeforemajor
modern-day advances in type 1 diabetes
treatment (self-monitoring of blood glu-
cose, A1C testing, and ACE inhibitors),
the speciﬁc effect of these advances can-
not be properly examined here.
Key strengths of this study include
the size of this population-based cohort
(n  1,075) and the 97% ascertainment
rate after 25 years of follow-up. In ad-
dition, we now have sufﬁcient follow-up
data for temporal trend and other analy-
ses in African Americans, providing im-
portantinformationforthisunderstudied
type 1 diabetes population (21).
In summary, these results are en-
couraging and provide contemporary,
population-based mortality ﬁgures for
individualswithlong-standingtype1di-
abetes. Women in our cohort die at a rate
similar to that of men, a result warranting
further exploration, as younger women
die much less frequently than younger
meninthegeneralU.S.population.These
data illustrate that mortality rates are
clearly decreasing in those in whom type
1 diabetes was diagnosed more recently;
however, those with diabetes diagnosed
mostrecently(1975–79)stilldieatrates5
times higher than that of the general pop-
ulation. Thus, continuing improvements
intreatmentandcareareessential,partic-
ularly in women and African Americans
with type 1 diabetes.
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